Evaluating only Proteomics startup Enumeral Biomedical’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
Founded in Cambridge, MA, to commercialize single B-cell technology for rapid antibody generation.
FUNDING
Secured NIH SBIR grants and NIAID partnership to develop Ebola and influenza rapid diagnostic tools.
PIVOT
Pivoted toward therapeutic antibody discovery after diagnostics revenue failed to materialize.
SHUTDOWN
Enumeral Biomedical silently shut down after exhausting $8M in equity and failing to raise Series A.
Full Analysis
Free · no account needed
Documented cause
Enumeral Biomedical developed single B-cell antibody discovery for infectious disease diagnostics including flu and Ebola. Despite partnerships with NIAID and NIH grants exceeding $3M, the company failed to convert research validation into commercial revenue. With only $8M raised from equity, the company could not afford Phase 2 clinical validation studies and shut down quietly in 2019 after burning through all capital.
Lesson
“Government grants validate science but don't replace venture capital needed for clinical commercialization.”